Molecular dynamics simulations of drug delivery liposomes and their interactions with bloodstream elements by Magarkar, Aniket
!Molecular) dynamics) simulations) of) drug) delivery)
liposomes)and)their)interactions)with)bloodstream)
elements)
)
Aniket)Magarkar)
University*of*Helsinki*
Faculty*of*Pharmacy*
 
Molecular Dynamics Simulations of Drug Delivery Liposomes 
and Their Interactions With Bloodstream Elements 
 
Aniket Magarkar 
 
Centre for Drug Research 
Division of Pharmaceutical Biosciences 
Faculty of Pharmacy 
University of Helsinki 
Finland 
 
 
 
 
Molecular dynamics simulations of drug delivery 
liposomes and their interactions with bloodstream 
elements 
 
 
 
 
 
 
Aniket Magarkar 
 
 
 
 
 
 
 
 
 
 
 
 
ACADEMIC DISSERTATION 
 
To be presented, with the permission of the Faculty of Pharmacy of University of 
Helsinki, for public examination to be held at Auditorium 1 at Viikki Korona 
Infocenter, Viikinkaari 11 on August 25th, 2014 at 11 AM. 
 
Helsinki 2014 
   2 
Supervisors:   Dr. Alex Bunker, PhD 
Centre for Drug Research 
Faculty of Pharmacy 
University of Helsinki, Helsinki, Finland 
 
Dr. Henri Xhaard, PhD 
Centre for Drug Research 
Faculty of Pharmacy 
University of Helsinki, Helsinki, Finland 
 
Reviewers:   Prof. Pavel Jungwirth, PhD 
Institute of Organic Chemistry and Biochemistry 
Academy of Sciences of the Czech Republic, Prague 
Czech Republic 
 
Prof. Peter Tieleman, PhD 
Department of Biological Sciences and  
Centre for Molecular Simulation  
University of Calgary, Calgary, 
Canada 
 
Opponent:   Prof. Roland Faller, PhD 
Department of Chemical Engineering and Materials 
Sciences, 
University of California, Davis, 
USA 
 
Thesis Committee: Prof. Arto Urtti, PhD 
Centre for Drug Research 
Faculty of Pharmacy 
University of Helsinki, Helsinki, Finland 
   
Prof. Marjo Yliperttula, PhD 
Centre for Drug Research 
Faculty of Pharmacy 
University of Helsinki, Helsinki, Finland 
 
Dr. Tomasz Róg, PhD 
Department of Physics 
Tampere University of Technology, Tampere, Finland 
  
ISBN 978-951-51-0097-9 (pbk.) 
ISBN 978-951-51-0098-6 (PDF, http://ethesis.helsinki.fi) Helsinki, 2014 
Cover: Cartoon representation of all atom model of polyethylene glycol coated drug 
delivery membrane bilayer in water with ions.  
 3 
Abstract 
Drug delivery is a vital issue in pharmaceutical research; once a drug candidate 
molecule is identified, it must be delivered to the target area of the body where it can 
take effect. In addition, non-specific distribution of drug molecules to areas other 
than the drug target must be decreased to avoid unwanted side effects. To achieve 
this, nanotechnological drug delivery systems can be used. Nanotechnological drug 
delivery systems come in a wide variety of forms, including liposomes, dendrimers, 
nanoparticles, and polymeric micelles. Of these, our research is focused on drug 
delivery liposomes. 
Drug delivery liposomes are composed of a membrane that forms a closed 
spherical sack, with a diameter of approximately 100 nm that can contain drug 
molecules. The criteria for effectiveness of these drug delivery liposomes (DDLs) 
are structural stability, its lifetime in the bloodstream, the release rate of the 
encapsulated content and site specific targeting. Cholesterol is one of the crucial 
lipid components of the DDL known to increase its stability. They also can have a 
protective polymer coating such as polyethylene glycol (PEG) that protects the DDL 
from the body’s defense mechanisms. Also the DDL can posses targeting moieties, 
able to direct the PEGylated liposomes to the specific target. In this study we have 
investigated surface structure of the DDL and its interactions with elements of the 
bloodstream. 
 
While it is difficult to determine an accurate picture of the DDL surface and its 
interactions with ions and bloodstream proteins with atomistic resolution by 
experiments alone, computational molecular modelling techniques can provide 
insights into it. Hence, we have used computational modelling and molecular 
dynamics simulations to understand the role of each component of the DDL in its 
structure.  
  
The three of the five reported studies in this thesis (I, II, III) are focused on how 
surface charge plays an important role in the liposome, how it is affected by various 
components of the DDLs, and how the specific interactions of DDLs and ions 
present in the bloodstream influence it. The chapter IV deals with understanding the 
properties by systematically varying components such as cholesterol and PEG. Also 
we have produced the first ever model of the first FDA approved drug delivery 
liposome (DOXIL ®) at atomistic resolution details.  The last study (V) deals with 
the application of molecular dynamics in targeted drug delivery research. In this 
study we could identify the reason for failure of specific novel targeting peptide 
(AETP), which is used to functionalize the DDL, by identifying its interactions with 
the protective PEG polymer. 
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The insights obtained by these studies can be used to improve the design of 
PEGylated or other polymer coated liposomes and will have the potential to lead to 
breakthroughs in drug delivery efficacy as these techniques can be applied to a wide 
range of therapies that involve delivery through the DDL. 
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1. Introduction 
Drug delivery is a vital issue in pharmaceutical research; once a drug candidate 
molecule is identified, it must be delivered to the desired biological target where it 
can take its effect. (Farokhzad & Langer 2009; Lasic 1998) In addition, non specific 
distribution of drug molecules to areas other than the drug target must be decreased 
to avoid unwanted side effects (Lasic 1998; Torchilin 2005a; Kang et al. 2010). Also 
in many cases, the potential drug molecule has unfavourable biochemical properties 
such as poor water-solubility and poor pharmacokinetic distribution. Encapsulation 
of the drug molecules in nano-scale drug delivery systems has shown particular 
promise in overcoming these limitations. (Cattel et al. 2003; Sapra et al. 2005). 
Nanotechnological drug delivery systems come in a wide variety of forms, including 
liposomes, dendrimers, nanoparticles, and polymeric micelles (Orive et al. 2003). Of 
these, our research is focused on drug delivery liposomes. Alec Bangham discovered 
liposomes in the 1960s. The first polymer-coated liposome was formulated by Peter 
Speiser in the 1970. So far there are more than twenty thousand research articles 
with keywords “liposome” and “drug delivery”. The research has been directed 
towards understanding of the properties of the DDL and characterizing their 
interactions with the constituents of blood plasma. Once these properties are 
understood in greater detail, efforts can be made towards increasing the half-life of 
the DDL in the bloodstream and designing better DDLs. 
Drug delivery liposomes are composed of a membrane bilayer that forms a 
closed spherical sack, with a diameter of approximately 100-200 nm that can contain 
drug molecules (Cattel et al. 2003). The membrane bilayer of the DDL consists of 
phospholipids, with a hydrophilic headgroup and two hydrophobic hydrocarbon 
chains. The composition of the DDL determines its biophysical properties. For 
example, altering the lengths of the hydrophobic chains and the extent of saturation 
alters the phase behaviour of the lipid. The phospholipid headgroups are responsible 
for interactions of the DDL with the blood plasma constituents. Drug delivery 
liposomes can also have a protective polymer coating, the most common being 
polyethylene glycol (PEG) that protects the liposome from the body’s defense 
mechanisms. The biochemical properties of the polymer, molar fraction of polymer 
in DDL composition and the length of the polymer determine the structure and 
properties of the protective polymer on the DDL. In most cases of clinically 
approved DDLs cholesterol is included. The addition of cholesterol is known to alter 
the biophysical properties of the bilayer such as increase in mechanical strength and 
decrease in permeability across the membrane bilayer. 
 
The interaction of drug delivery liposomes with bloodstream proteins has been 
the subject of many experimental studies. The results of these studies are, however, 
as of yet, unclear. While it is difficult to directly determine an accurate picture of the 
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liposome surface and its interactions with bloodstream proteins experimentally at 
nano-scale resolution and nano-second time scale, computational molecular 
modelling is capable of providing insight into this. 
 
In the studies presented here, we have used molecular modelling as a tool to 
study the effect of varying the formulation of the DDL on the surface structure of the 
DDL and its interaction with ions present in the bloodstream. The results discussed 
in this study are expected to provide insight that can be used in the rational design of 
improved drug delivery liposomes. 
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2. Literature review 
One of the major challenges faced today in DDL based drug delivery is to 
understand the physicochemical properties, which are responsible for the 
performance of the DDL in vivo. Liposomes and liposome based drug delivery is an 
active field of research since the 1960s and there exists a considerable amount of 
knowledge concerning its properties gained from in vitro, in vivo and in silico 
studies. In this section, we discuss and summarize the available results from the 
research reported to date, regarding the topics covered in our studies (and which are 
not covered in original articles included in this thesis).  
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1: Generic structure of liposome formed with membrane bilayer, showing 
hydrophilic head groups, hydrophobic acyl tails and aqueous pore of the liposome.  
 
2.1 Liposomes 
 
Liposomes are self-assembling spherical lipid bilayer vesicles with an internal 
aqueous core. (Figure 1) The lipid bilayer of the liposome is composed of 
amphiphilic natural or synthetic phospholipid molecules. The lipid molecule has one 
hydrophilic head group attached to two hydrophobic lipid tails consisting of acyl 
chains. The length of the hydrocarbon tails of the phospholipid ranges from 8 to 18 
Hydrophilic+head++
Hydrophobic+tails+
Aqueous+pore+
Phospha5dylcholine+(PC)+ Phospha5dylehtanolamine+(PE)+ Phospha5dylglycerol+(PG)++
Lipid+Head+groups+
Liposome+
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carbons, which can be either saturated or unsaturated. The longer saturated acyl 
chain results in the gel phase of the membrane (Figure 2), in contrast, a shorter 
hydrocarbon chain imparts liquid crystalline structure to the membrane bilayers 
(Figure 2). Depending on the chemical composition of the lipid headgroup it can 
either be zwitterionic, e.g. phosphatidylcholine (PC) and phosphatidylethanolamine 
(PE), or positively charged, e.g. 3-trimethylammonium-propane (TAP), or 
negatively charged, e.g. phosphatidylglycerol (PG). Apart from phospholipids, 
cholesterol is included in the DDL membrane bilayer, and is known to play a role in 
increasing the mechanical strength of the membrane bilayer and decreasing the 
permeability of the membrane. Due to the amphiphilic nature of the DDL, it can 
encapsulate both hydrophobic and hydrophilic drug molecules. The aqueous core of 
the DDL can be loaded with hydrophilic drug molecules and hydrophobic drugs can 
reside in the lipid tail regions of the membrane bilayers (Sadzuka et al. 2002).  
  
  
         A              B 
Figure 2: Effect of acyl chain length on the nature of membrane bilayer. 
(A) DSPC membrane bilayer in the gel state 
(B) DLPC membrane bilayer in the liquid-crystalline state 
 
2.2 Liposome based DDLs 
 
Liposome based nanoparticles have proven to reduce the side effects of toxic 
anti-cancer drugs. Liposome based DDLs are one of the four available nanoparticle 
based FDA approved therapeutics. The Doxil®, DaunoXome®, and Marqibo® are 
the DDL therapeutics have so far been approved by FDA. The Doxil® formulation 
reduces the cardiotoxicity associated with free doxorubicin. Doxil® has been used in 
the treatment of AIDS-related Kaposi's sarcoma (FDA approval: 1995), ovarian 
cancer (FDA approval: 1999), and for multiple myeloma (FDA approval: 2007) 
(Sadzuka et al. 2006). DaunoXome and Marqibo are used for the treatment of 
Kaposi's sarcoma and leukaemia respectively. Doxil contains DSPE-PEG-2000, 
which is known to prolong its bloodstream half-life up to 3-4 days (Jiang et al. 
2011). From in vivo experiments it is known that PEGylated liposomes accumulate 
at the tumor site due to the enhanced permeability retention (EPR) effect (discussed 
further) (Li et al. 1998; Schiffelers et al. 2005), however the exact mechanism of 
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drug release from the liposomes and uptake by tumor cells is not currently well 
understood.  
 
Due to a lack of understanding of the exact mechanism of the drug release from 
the DDL and its interactions with blood plasma, all available FDA approved DDL 
therapeutics rely on passive accumulation at the target site via the EPR effect. 
Although there have been many attempts made already for the active targeting of 
DDLs to the specific target site, so far there are no FDA approved targeted DDL 
therapeutics available (Immordino et al. 2006; Maruyama et al. 1997).  
 
2.3 Passive targeting and active targeting of the DDL 
 
2.3.1 Passive targeting via the EPR effect 
 
For the case of cancer, the targeting of the DDL to the desired location is 
achieved through passive targeting. As the tumor continues to grow (up to 1-2 mm3), 
in order to meet increased demand from the growing mass of cells for oxygen and 
nutrients, there begins the formation of new blood vessels termed as angiogenesis. 
The process of angiogenesis can be up regulated by vascular endothelial growth 
factor (VEGF), platelet derived growth factor (PDGF), and tumor necrosis factor-α 
(TNFα), and down regulated by angiogenic inhibitors, such as thrombospondin-1. 
The morphology of this new tumor vasculature differs from the normal tissue, as it is 
inherently leaky. Thus, due to a drastic increase in permeability in vasculature at 
tumor site, there is higher accumulation of the DDL. This effect is termed as the EPR 
effect (Fang et al. 2011; Maeda 2012; Jain & Stylianopoulos 2010; Torchilin 2011). 
The EPR effect has been demonstrated to achieve 10–50 fold local concentrations of 
nanoparticles in the tumor in comparison to normal tissues (Iyer et al. 2006) (Fang et 
al. 2011; Maeda 2010; Jain 1987; Maeda et al. 2009). In order for the DDL to be 
accumulated at the tumor site, increased half-life in the bloodstream is essential. 
Also the size of the nanoparticle is a crucial factor, it should have a diameter less 
than 100 nm to prevent accumulation in the liver and more than 10 ns to prevent 
filtration by the kidneys (Danhier, Feron & Preat 2010). 
 
2.3.2 Active targeting 
 
In order to increase the accumulation of DDLs at specific targeting sites, the 
target specific moieties (peptide or antibodies) are attached on the surface of the 
liposome or attached at the end of the protective polymer of the DDL. (Sapra, Allen 
2003). The targeting moieties can be antibodies (ElBayoumi, Torchilin 2009, 
Pastorino et al. 2003b, Iyer et al. 2011), peptides (Moreira et al. 2001, Temming et 
al. 2005, Xiong et al. 2005), small molecule ligands (Gabizon et al. 1999, Voinea et 
al. 2002, Riviere et al. 2011) or specific sugar molecules (David et al. 2004). The 
advantage of the active targeting includes the accumulation of DDLs and release-
encapsulated drug from the DDL only at the targeted site. Despite recent efforts to 
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achieve this, in vitro and in vivo, to date there are no FDA approved active targeted 
DDLs achieved yet. 
 
2.4 Surface charge 
 
Surface charge of the DDL is known to affect its half-life in the bloodstream and 
its tissue distribution as well as cellular uptake at the target site (Capriotti, 
Caracciolo, Cavaliere, Foglia, et al. 2012). Also surface charge of the DDL plays a 
major role in its interactions with opsonin proteins which initiate the process of 
internalization of DDL by the macrophages, and thus accelerate elimination from 
bloodstream (Yan et al. 2005, Patel et al. 2011).  
 
It has been noted that neutrally charged liposomes have exhibited significantly 
enhanced accumulation at the tumor site and tumor vasculature in comparison to the 
charged ones (Krasnici et al. 2003). Also, several studies have indicated that charged 
DDLs have shorter half-life in the bloodstream as they activate the complement 
pathway of the immune system strongly in comparison t bloodstream bloodstream o 
neutral DDLs (Krasnici et al. 2003). An extensive in vivo study showed that charged 
DDLs containing phosphatidylglycerol (PG), phosphatidic acid (PA), cardiolipin 
(CL), phosphatidylinositol (PI), or phosphatidylserine (PS) activate the classical 
immune pathway, with promoting interaction with C1q protein. (Bradley et al., 
1999a,b; Chonn et al., 1991a; Devine et al., 1994). Also, the DDLs containing 
cationic lipids such as DOTAP, have been shown to promote the activation of the 
alternate immune pathway in vivo (Chonn et al., 1991a). Also an interesting study by 
Ishida et al. (2001) demonstrated that the cholesterol content in DDL plays a key role 
in the decision of which immune pathway will be activated (classical or alternate 
pathway). They showed that, 33-mol% or less cholesterol activated complement via 
the classical pathway, while liposomes with 44-mol% cholesterol activated the 
complement system through the alternative pathway. They could not, however 
explain the reason for this observation. With our in silico and in vitro studies, we 
have shown that cholesterol content in the DDL affects its surface charge and thus 
provide a possible explanation for this observation. 
 
2.5 Effect of PEGylation on the DDL 
 
Polyethylene glycol is one of the predominant protective polymers used for 
coating the DDL. Although it is known to increase the bloodstream lifetime, the 
exact mechanism through which it achieves this, is still unclear. The results from the 
reported studies so far have been conflicting, which makes it difficult to derive any 
heuristics on the possible mechanism through which PEG can prolong the half-life of 
the DDL in circulation. 
 
On incorporating PEG in anionic liposomes at 5-10% molar concentration, 
Bradley et al. (1998) noticed inhibition of complement activation mediated through 
C1q protein binding to the DDL; in another study by Szebeni et al. (2002), they 
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demonstrated activation of the complement pathway after inclusion of PEG in the 
DDL formulation; and in contrast Price et al. (2001) observed no effect of 
PEGylation of the DDL at all on either activation or prevention of the complement 
pathway.  
 
The deposition of complement pathway proteins and opsonins on the PEGylated 
DDL surface leads to uptake of the DDL by macrophages (Moghimi and Szebeni, 
2003). These findings were attributed to the negative charge on the phosphodiester 
group of DSPE. It has been reported that upon repeating the dose of PEGylated DDL 
in vivo, its blood half-life decreases significantly, and its uptake by the liver 
increases suggesting involvement of soluble serum factors in the process. (Bendas et 
al., 2003; Dams et al., 2000; Ishida et al., 2003a,b; Laverman et al., 2001a,b). This 
phenomenon is termed as accelerated blood clearance (ABC). (Dams et al., 2000; 
Laverman et al., 2001b) PEGylation is not responsible for this effect though, as non-
PEGylated DDLs shows similar response to the ABC effect.  
 
Cullis et al. (1998) showed that, the formulation density of the PEGylated lipid is 
an important factor dictating its interactions with protein in the bloodstream. This 
finding was also confirmed by Ishida et al (2004), where they showed only when the 
PEG formulation density is increased to 10% in the DDL, its interactions with 
proteins was minimized with serum proteins.  
 
Other than immune system proteins, PEGylated DDLs can also weakly bind to 
the serum albumin, which is predominantly present in blood. Johnstone et al. (2001) 
demonstrated that incubating PEGylated DDLs with serum reduced uptake by 
macrophages for the case of neutral, cationic and anionic DDLs. They concluded 
that, interaction with serum albumin might have altered the DDLs properties, which 
have provided protection against the proteins of the immune system. It has been 
shown that one of the ways that PEG enhances circulation time of the DDL is by 
preventing their aggregation. (Allen et al., 2002, Ahl et al. 1997) These studies 
question the widely accepted phenomenon of prevention of opsonization by PEG, by 
providing a steric barrier alone to the interactions of proteins with DDL. Thus a clear 
picture is required with advanced analytical experiments and modelling to 
understand the above results. 
  
2.6 Protein corona of DDL 
 
Upon introduction of the DDL into circulation in vivo, different protein 
molecules present in bloodstream rapidly adsorb to DDL. These loosely bound 
proteins on the DDL is known as the “protein corona”; and it varies from DDL to 
DDL based on its physicochemical characteristics such as size, surface charge and 
lipid composition (Chonn et al., 1992; Johnstone et al., 2001; Moghimi and Patel, 
1988). This protein corona dictates the fate of the DDL. (Since 2002, there have been 
efforts going on to characterize this protein corona of the DDL. Understanding 
constituent proteins of corona will help understand the mode of action of DDL in 
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details. Typically this protein corona consists of complex mixture of opsonins, 
fibrinogens, immunoglobulins and complement proteins. All of these proteins are 
recognized by the mononuclear phagocyte system and thus cleared rapidly from the 
blood circulation (Monopoli et al. 2012).  It has been shown that PEGylation helps 
reduce the protein binding to the DDL, but does not prevent it completely. Thus the 
bio-distribution and targeting of the PEGylated DDL is also dependent on the 
adsorbed protein corona in the bloodstream. (Thus the precise knowledge of the 
constituents of the protein corona will help understand it better. (Barrán-Berdón et 
al. 2013; Capriotti, Caracciolo, Cavaliere & Foglia 2012a) Recent studies from 
Wolfram et al. revealed that, when PEGyated as well as non-PEGylated DDLs where 
incubated with serum, the changes in the zeta potential was observed in both cases 
(Wolfram et al. 2014). The characteristics of PEGylated and non-PEGylated DDLs 
differed significantly due to the different protein corona content of the both. 
Lundqvist et al. have reported that the nature and component of the protein corona 
can change according to the surface properties and size of the DDL despite being 
composed of same material.  (Lundqvist et al. 2008) This will result in an entirely 
different biological fate of the two DDLs formulated with same material but having 
different size. 
Advanced analytical techniques are being implemented such as isothermal 
titration calorimetry, surface plasmon resonance and size exclusion chromatography 
for studying the affinity and stoichiometry of protein binding to nanoparticles. 
Coupling these experimental studies with molecular modelling techniques will 
certainly help understand the specific interactions of DDLs with protein corona in 
detail. 
2.7 Computational simulations of lipids and ions 
 
Lipids are the predominant component of the cell, as it constitutes membranes, 
lipoproteins and lipid droplets. (Sackmann 1995; Mouritsen 2005; van Meer 2005) 
Lipids mediate or facilitate varied molecular interactions such as protein functions, 
signaling and transfer of molecules across them (Simon 2006; Simons 2010). For 
these reasons, lipids have been studied extensively in vitro, in vivo as well as in 
silico. As with experiments alone it is difficult to access atomic resolution and the 
timescales of less than a microsecond, coupling them with MD simulations have 
helped gain an understanding of the biological phenomena involving ion channels 
and membrane protein interactions (VR, Bjelkmar 2009; Bucher et al. 2010; Fan et 
al. 2010).  
 
Kox et al. reported the first simulation of lipids in 1980, consisting of 32 lipids 
for 80 ps. Since then there have been many more reported studies exploring various 
aspects of the membrane bilayers and their interactions with ions as well as 
biological macromolecules. Czaplewski et al. presented the first extensive study 
encompassing MD simulations of different hydrated PC lipid bilayers with and 
without sterols. (Czaplewski 2000) Later in 2004, Mukhopardhyay et al. reported the 
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interactions of ions with the hydrated membrane bilayers (Mukhopadhyay et al. 
2004). The exact mechanism of the interactions of the Na+ with PC membrane were 
reported by Vácha et al. (VAcha et al. 2009; VAcha et al. 2010).   
 
Recently reported MD simulations of membranes, consisting of ~1000 lipids are 
performed over a microsecond timescale at atomistic resolutions (Dror et al. 2012). 
Also, coarse-grained MD simulations allow to access longer timescales (discussed in 
the MD simulations chapter), by approximating the set of atoms or functional group 
to a bead, which essentially reduces the number of particles under consideration in 
MD simulation (Marrink et al. 2004, 2007; Monticelli et al. 2008; Lopez et al. 
2009;Ayton and Voth 2009; Murtola et al. 2009). 
 
In our MD simulation studies we build upon this existing knowledge of hydrated 
membrane bilayer and ion interactions in order to answer the question relevant to 
pharmaceutical drug delivery.  
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3. Aims of the study 
The general objective of the study was to understand the surface structure and the 
properties of the DDL with and without PEG and its interactions with the ions in the 
bloodstream. We have used molecular dynamics to study the DDL model for all 
cases. These computational simulations were coupled with in vitro and in vivo 
experimental validations in studies in I and V respectively.  
 
The specific aims were as follows: 
 
1. Investigate the role of cholesterol in drug delivery liposomes structure 
2. Investigate surface structure and properties of the membrane bilayer 
composed of novel synthetic DLCPe lipids, where the positions of the 
phosphate and choline groups are exchanged from their positions in regular 
phospholipids. 
3. Study of the effects of different salts present in bloodstream such as NaCl, 
KCl and CaCl2 and effect of salt concentration on the surface structure of the 
PEGylated liposome. 
4. Understand the interactions at the PEGylated liposome structure containing 
cholesterol and build the first model for the Doxil® formulation with 
atomistic level resolution. 
5. Investigate the reason for the failure of a new cancer targeting peptide in the 
PEGylated liposome through computational molecular dynamics and 
molecular docking. 
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4. Overview of the methods 
4.1 Molecular dynamics simulations 
 
All atom molecular dynamics simulation implemented through the Gromacs package 
4.5 (Pronk et al. 2013) was used for all the studies to look at the structure and 
interactions of the liposome  (I – V).  
 
4.1.1 Overview 
 
Figure 3: Available biophysical techniques for analysing biomolecules and their 
interactions spatiotemporally. The x-axis denotes the time scales of events occurring 
in cells and the y-axis denotes, the size of the biological structures. Each colored box 
in the plot shows a technique which can be used to examine the specified biological 
event and at the specific length scale (Dror et al. 2012). 
The biomolecules themselves and their interactions are highly dynamic in nature 
and their motions are often critical to their function. Molecular dynamics simulations 
can examine these dynamic motions and interactions of macromolecules with atomic 
resolution. In some way it can be looked at as a computational microscope, capable 
of revealing biomolecular mechanisms at spatial and temporal scales, which are 
difficult to observe by present experimental techniques. (The typical biochemical 
processes that can be viewed by MD simulations include, protein folding, drug 
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binding, membrane transport, and the conformational changes critical to protein 
function (Karplus 2002). 
 
4.1.2 MD algorithms  
 
The all-atom MD simulation includes a description of each atom in the simulated 
system. After describing the system, at each iterative step the forces acting on each 
atom are computed using Newton's laws of motion to update its position and 
velocity. The mathematical equation to calculate the physical force on the atom is 
called a force field. It has three components: 
 
1. Bonded interaction forces - interactions between small groups of atoms 
connected by covalent bonds 
2. van der Waals forces - short range interactions among all pairs of atoms in 
the system  
3. Electrostatic forces - interactions among all pairs of atoms, this fall off 
slowly with distance.  
 
For nearby pairs of atoms, electrostatic interactions are computed explicitly. 
However the long-range electrostatic interactions are calculated by approximate 
methods to speed up the calculations. 
 
4.1.3 Force fields  
 
In classical MD, interactions between the particles are modelled by a potential 
energy function called a force field, which calculates sums of multi-body potentials 
including bond stretching, angle bending, torsional twisting, out-of-plane bending, 
Lennard-Jones (LJ) interactions and Coulomb interactions.  
 
A general force field can be written as follows (note: the particular force field may 
contain additional terms) 
 
 
where, 
V= potential energy function 
r = position vector (for all particles) 
b, rij = inter-particle distance 
θ = bond angle 
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13.2.1 General Issues of Force Fields
In classical MD simulations, atoms are often reduced to point-like particles. The
interactions between the particles are typically modeled by sums of pairwise or
multibody potentials including bond stretching, angle bending, torsional twisting,
out-of-plane bending, Lennard-Jones (LJ) interactions and Coulomb interactions.
A general form of the potential energy function can be written as,
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although there may be some extra terms in certain force fields. The potential energy
function V is dependent on position vector r of all particles, from which the inter-
particle distance b and rij, the angle ! , the dihedral angle ® and the improper dihedral
angle in the expression are derived. The parameters in bonded terms, including the
force constants kb, k! , k®, k and the equilibration distance b0, angle !0, improper
angle  0, dihedral phase angle ®0 and multiplicity n, and those in non-bonded
terms, including the LJ well depth "ij, the collision diameter # ij, and the partial
particle charges qi and qj, are all dependent on the particle type involved in each
term. "D is the dielectric constant. The functional form of potential energy and the
set of parameters constitute a force field. The parameters in force fields are derived
from a combination of experimental data and quantum mechanical calculations [6].
Parameterized force fields are computationally efficient and allow for simulation of
biomolecules with hundreds of thousands of atoms for hundreds of nanoseconds.
A good force field should provide satisfactory agreement with all available
experimental data and a well determined parameter set is crucial to its accuracy. In
parameter development, a basic assumption is often adopted that the particles bear-
ing similar chemical environment can share the same parameters (partial charges
are sometimes treated more specifically). For example, backbone carbonyl groups
and amino groups in proteins are often regarded to be the same to the groups in N-
methylacetamide, and methyl groups in amino acid side chains are treated equally
with those in alkanes. This assumption greatly reduces the number of parameters as
all particles involved are now reduced to a few particle types and the same parameter
set can be transferred between particles of the same type, thereby simplifies
the parameter optimization procedure. In practice, a large biomolecule is usually
divided into appropriate model molecules of about ten heavy atoms. Then parameter
optimization can be conducted individually for each small molecule by fitting to
its quantum mechanical calculation results and experimental data. The resulted
parameters are directly transferred to the original biomolecules and further verified
 22 
φ = dihedral angle 
ψ = improper dihedral angle 
kb, kθ, kφ, kψ = respective force constants  
q = partial charge 
εD = dielectric constant 
 
The parameters for the force fields are derived from a combination of experimental 
data and quantum mechanical calculations.  
The most commonly used force fields for all-atom simulations are CHARMM 
(MacKerell et al. 1998), AMBER (Case et al. 2005) and OPLS (Jorgensen & 
Maxwell 1996). All of these force fields have been validated with various 
experiments. In all of our studies we have used OPLS all atom force field. The 
specific details for the MD simulations are discussed in respective chapters. 
 
4.1.4 Limitations of molecular dynamics simulations 
 
Molecular dynamics simulations have been an active area of research for more 
than 40 years, and so far have faced two major challenges. The first is the 
“computational expense of the MD simulation” that is how fast the calculations can 
be performed; this limits the overall timescales for the biomolecular interaction. 
Second challenge is the development of force fields and the approximations 
considered in them. Together these two limit the length and their accuracy of MD 
simulations. 
 
As described above, the relevant timescale for the events in the biological 
system ranges from the level of nanoseconds to seconds. The longest molecular 
dynamics simulation reported so far is few milliseconds and considered state of the 
art today. These simulations can model protein folding (for small and fast folding 
protein), drug binding, membrane transport, and the conformational changes critical 
to protein function. Though there are very few cases that involve millisecond long 
simulation due to their computational demands. As the molecular force fields 
available today involve appropriate modelling of the relevant underlying physics, 
they have been restricted in their accuracy (e.g. Non-polarizable force-fields which 
underestimate the amount of the dielectric response in low-dielectric protein 
environment and lipid membranes). (Monticelli & Tieleman 2012) Also most of the 
MD simulations do not yet completely capture the detailed molecular composition of 
biological systems, which consists of various types of molecules. Lastly, classical 
MD simulations treat covalent bonds as an assumed parameter of the simulation, as 
bonds are not able to break or make. Hence, chemical reactions involving 
breaking/making of covalent bonds cannot be simulated. There are other hybrid 
computational methods such as quantum mechanics/molecular mechanics (QM/MM) 
simulations, which can help solve this problem (Kamerlin & Warshel 2011; Senn & 
Thiel 2009). Since quantum mechanical simulations are computationally expensive, 
the time and length scale that can be examined with them is extremely limited.  
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4.2 Molecular Docking 
 
4.2.1 Overview 
 
The biological process involves communication between biomolecules by molecular 
interactions. Molecular docking is the method to predict these interactions by 
predicting the global minimum in the interaction energy between the small 
molecule/hit/lead/drug and the target molecules for e.g. protein, by exploring all 
available degrees of freedom for the system. By understanding these interactions, 
novel molecules can be designed which can be then used to control specific 
biological processes, by optimizing the required interactions. 
 
4.2.2 Autodock 
 
Autodock is one of the several available molecular docking packages, which 
was used in our study (chapter V), to understand the comparison between 
interactions of HSA with different component of the PEGylated liposome with 
targeting moieties. Autodock has automated procedure for predicting the interaction 
of ligands with bio-macromolecular targets. The Autodock utilizes the Lamarckian 
Genetic Algorithm and empirical free energy scoring function, to provide docking 
results for ligands with approximately 10-20 flexible bonds. It uses semi-empirical 
free energy force field (Autodock force field) to evaluate conformations during 
docking simulations. This force field was parameterized using a large number of 
protein-inhibitor complexes for which both structure and inhibition constants, or Ki, 
are known.  
 
4.2.3 Force field for scoring the interactions 
 
The force field can evaluate binding of the biomolecules in two steps.  
 
1. Intra-molecular energetics is estimated for the transition-unbound states to the 
conformation of the ligand and target protein in the bound state.  
2. Evaluation of the intermolecular energetics of combining the ligand and protein in 
there bound conformation. 
 
The force field includes six pair-wise evaluations (V) and an estimate of the 
conformational entropy lost upon binding (ΔSconf) by:  
 
where, 
 L = ligand  
 P = protein  
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Theory 
Overvi w o  the Free En rg  Scorin Function 
Aut Dock 4.2 us s a semi-empirical fr e energy for e field to evaluate conformations during 
docking simulations. The force field was parameterized using a large number of protein-inhibitor 
complexes f r which both structure and inhibition constants, or Ki, are known.  
 
The force field evaluates binding in two steps. The ligand and protein start in an unbound 
conformation. In the first step, the intramolecular energetics are estimated for the transition from 
these unbound states to the conformation of the ligand and protein in the bound state. The second 
step then evaluates the intermolecular energetics of combining the ligand and protein in their 
bound conformation. 
The force field includes six pair-wise evaluations (V) and an estimate of the conformational 
entropy lost upon binding (ΔSconf): 
€ 
ΔG = (Vbound
L−L
−Vunbound
L−L
)+(Vbound
P−P
−Vunbound
P−P
)+(Vbound
P−L
−Vunbound
P−L
+ΔSconf )  
where L refers to the “ligand” and P refers to the “protein” in a ligand-protein docking 
calculation. 
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Each of the pair-wise energetic terms includes evaluations for repulsion, hydrogen 
bonding, electrostatics, and desolvation:  
 
 
 
In the equation X, W represents weighting constant, which is optimized to calibrate 
the empirical free energy based on a set of experimentally determined binding 
constants.  
First term = typical 6/12 potential for dispersion/repulsion interactions. (Based on 
Amber force field) (Anon 2014)  
Second term= H-bond term based on a 10/12 potential (C and D are assigned to give 
a maximal well depth of 5 kcal/mol at 1.9Å for hydrogen bonds with oxygen and 
nitrogen, and a well depth of 1 kcal/mol at 2.5Å for hydrogen bonds with sulphur). 
E(t) provides directionality based on the angle t from ideal H-bonding geometry.  
Third term = Coulomb potential for electrostatics 
Fourth term = Desolvation potential based on the volume of atoms (V) that surround 
a given atom and shelter it from solvent, weighted by a solvation parameter (S) and 
an exponential term with distance-weighting factor σ=3.5Å (Morris et al. 2009). 
 
4.2.4 Limitations of molecular docking 
 
The docking protocols are improving significantly in force field parameters (Karaca 
& Bonvin 2013). Molecular docking is able to correctly predict the molecular pose 
of interactions, however, the main issue remains scoring and ranking of the various 
obtained poses. Due to this, the amount of false positives obtained is significantly 
higher (Dror 2012), hence one needs to validate the results obtained by molecular 
docking by complementary experiments. Also the entropic contribution in ligand-
receptor interactions is an important factor in binding energy calculations and is very 
difficult to be considered in docking protocols. Kongsted et al. and Coutinho et al. 
and have attempted to factor in the entropic component in the docking calculations 
which have increased the accuracy of the scoring functions. These approached 
include, taking into account the interactions from water shell (4A ̊) around the protein 
molecules to minimize the changes in the protein geometry or calculating the loss in 
torsional, vibrational, rotational and translational free energies of the ligand upon 
binding with the receptor. 
 
In this section, the brief details of the molecular modelling methodologies and their 
limitations are summarized.  The exact details and parameters of the methodologies 
used in each of the study are mentioned in the respective chapters I-V in the next 
section. 
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Each of the pair-wise energetic terms includes evaluations for dispersion/repulsion, hydrogen 
bonding, electrostatics, and desolvation: 
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The weighting constants W have been optimized to calibrate the empirical free energy based on a 
set of experimentally determined binding constants. The first term is a typical 6/12 potential for 
dispersion/repulsion interactions. The parameters are based on the Amber force field. The second 
term is a directional H-bond term based on a 10/12 potential. The parameters C and D are 
assigned to give a maximal w ll depth of 5 kcal/mol at 1.9Å for hydrogen bonds with oxygen 
and nitrogen, and a well depth of 1 kcal/mol at 2.5Å for hydrogen bonds with sulfur. The 
function E(t) provides directionality based on the angle t from ideal H-bonding geometry. The 
third term is a screened Coulomb potential for electrostatics. The final term is a desolvation 
poten ial based on the volume of atoms (V) that surr und a given atom and shelter it from 
solvent, weighted by a solvation parameter (S) and an exponential term with distance-weighting 
factor σ=3.5Å. For a detailed presentation of these functions, please see our published reports, 
included in Appendix IV. 
By default, AutoGrid and AutoDock use a stand rd set of parameters and weights for the force 
field. The parameter_file keyword may be used, however, to use custom parameter files. 
The format of the parameter file is described in Appendix I. 
Several methods for estimating he contribution of the unbound st e are implemented in 
AutoDock. In Autodock 3.0 and earlier versions, an assumption is made that the unbound form 
of the ligand (VL-Lbound in the equation above) is the same as the final docked conformation of the 
ligand (VL-Lunbound ), yielding a final contribution V
L-L
bound -V
L-L
unbound = 0.  AutoDock 4.1  
introduced a method of generating an extended form of the ligand to model the unbound state. 
Reports from users, however, revealed that the method caused significant problems with 
sterically-crowded molecules, and the default method was changed to the bound=unbound 
assumption in AutoDock 4.2 and later. In addition, there is an option for a user-defined unbound 
state. 
Dispersion/repulsion,
interac0on,
,
Hydrogen,bonds, Electrosta0c,,
interac0on,
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10. Summary of the main results !
in silico 
/in vitro Property Materials Result Publication 
in silico Ion binding to membrane headgroups 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM 
Na+ is highest in the absence of 
cholesterol ~48% and decreases 
with increase in cholesterol to 
~20% I 
POPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1  in 
presence of NaCl at 125 mM 
Na+ is highest in the absence of 
cholesterol ~45% and decreases 
with increase in cholesterol to 
~16% 
in silico Charge  density 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM 
Charge density decreases as 
cholesterol content increases 
I POPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1  in 
presence of NaCl at 125 mM 
Charge density decreases as 
cholesterol content increases 
in vitro ζ potential 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM 
Zeta potential is maximum in 
absence of choleasterol, wiz 
~2mV and drops down to ~-6 
with increase in cholesterol in 
presence of saline I 
POPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1  in 
presence of NaCl at 125 mM 
Zeta potential is maximum in 
absence of choleasterol, wiz 
~1mV and drops down to ~-2 
with increase in cholesterol in 
presence of saline 
in silico Mass density profile DSPC:Chol membrane bilayer with 6:0, 5:1, 4:1 in presence of NaCl at 
With increase in cholesterol 
content, Na+ peak is shifted away I 
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125 mM from the membrane bilayer 
POPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1  in 
presence of NaCl at 125 mM 
With increase in cholesterol 
content, Na+ peak is shifted away 
from the membrane bilayer 
in silico Area per lipid of bilayer 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM 
With increase in cholesterol 
content, area per lipid decreases I 
POPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1  in 
presence of NaCl at 125 mM   
in silico 
Mass density plot 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM NaCl 
Na+ peak shifts away from the 
membrane bilayer in case of 
DLCPe as compared to DLPC 
II 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM KCl 
K+ does not absorb to the 
membrane bilayer in both DLPC 
and DLCPe membranes 
 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM CaCl2 
Ca2+ peak shifts away from the 
membrane bilayer in case of 
DLCPe as compared to DLPC 
in silico Water ordering 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM NaCl Comparing the DLPC with DLCPe, in case of all systems, 
water ordering is plot shows 
reversal in the orientation of 
water molecules with respect to 
membrane normal 
II 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM KCl 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM CaCl2 
in silico Electrostatic potential across membrane 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
In cases of all 3 salts (NaCl, KCl 
and CaCl2) . The peak at the II 
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bilayer mM NaCl potential in the headgroup region 
is shifted towards the bilayer 
center and is roughly 0.15 mv 
higher for the case of the CPe 
lipids than for the PC lipids. 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM KCl 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM CaCl2 
in silico Rotational motion of headgroups 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM NaCl The rotation of CPe shows negligible dependence on the 
variety of salt present, while for 
the case of the PC bilayer, the 
type of salt affects the rotational 
motion of the headgroup. 
II 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM KCl 
DLPC membrane bilayer and 
DLCPe membrane bilayer with 125 
mM CaCl2 
in silico Mass density profile 
DSPC membrane bilayer with PEG 
at 10% formulations density with 
125nM NaCl and 0mM NaCl (only 
counter ions) 
In the presence of the Cl− anions 
shifts the Na+ in the PEG layer 
further out into the layer. The 
presence of salt can also be seen 
to expand the PEG layer slightly, 
for the liquid crystalline (DLPC) 
case also increasing the depth of 
its penetration into the membrane 
interior. 
III 
in silico 
in silico 
Mass density profile 
Ion binding to PEG 
oxygens 
DLPC membrane bilayer with PEG 
at 10% formulations density with 
125nM NaCl and 0mM NaCl (only 
counter ions) 
In the presence of the Cl− anions 
shifts the Na+ in the PEG layer 
further out into the layer. The 
presence of salt can also be seen 
to expand the PEG layer slightly, 
 
Comparison of Na+, K+, Ca2+ ions III 
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mass density profiles at 125 mM 
with DSPC membrane bilayer at 
10% PEG formulation density 
for the liquid crystalline (DLPC) 
case also increasing the depth of 
its penetration into the membrane 
interior. 
Na+ strongly interact with PEG 
oxygens (66.4%), K+ moderately 
interact with PEG oxygens(25%) 
and its non existent for the Ca2+ 
ions 
in silico Area per lipid of bilayer 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM with 
10% PEG formulation density 
With increase in cholesterol 
content at 10% PEG formulation 
density, area per lipid decreases 
from 0% to 16.67% of cholesterol 
then increases with increase in 
cholesterol till 50% 
IV 
in silico Visualization 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM with 
10% PEG formulation density 
PEG enters the membrane bilayer 
in presence of cholesterol while 
when it is absent, it doesn't enter 
DSPC membrane bilayer 
IV 
in silico Visualization 
DSPC:Chol membrane bilayer with 
6:0, 5:1, 4:1, 3:1, 2:1, 1:1 in 
presence of NaCl at 125 mM with 
10% PEG formulation density 
PEG interacts with cholesterol in 
a specific way interacting with β 
side of cholesterol 
IV 
   
Cellular affinity for AETP 
liposomes  did not increase  of 
liposomes in HUVEC-cells. 
V 
 
 
 
Pharmacokinetics  
Cytotoxic efficacy of 
doxorubicin-loaded AETP 
liposomes did not increase in 
HUVEC or SVEC4-10 cells. 
V 
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in vivo  
Pharmacokinetics 
Uptake in tumor 
 
AETP-targeted liposomes 
showed similar elimination half-
life (~7–10 h) to non-targeted 
liposomes (~6–7 h). 
V 
 
No significant differences in co-
localization of liposomes and 
endothelial cells observed 
between the AETP-targeted and 
non-targeted liposomes in 
confocal microscopy. 
V 
  
No significant difference in 
tumoral uptake between AETP-
targeted and non-targeted 
liposomes could be seen. 
V 
in silico Solvent accesable surface area 
DLPC and DSPC membrane bilayer 
with 10% PEG formulation density 
at X% targeting moeities RGD and 
AETP 
Computational modeling revealed 
that both AETP and RGD 
peptides located in the PEG 
region of the PEGylated 
liposomes. However, AETP was 
more covered by the PEG chains, 
while RGD was more exposed to 
the solvent. 
V 
in silico Molecular docking HAS with PEG, AETP, and RGD peptide 
Protein-ligand docking showed 
HSA having  stronger binding 
affinity to PEG and to AETP than 
to RGD peptide. 
V 
!
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11. General discussion 
11.1. Surface charge of the DDL 
 
Surface charge of the DDL is one of the important properties responsible for 
its interactions with the proteins in the bloodstream. Hence, in order to maximize 
the DDLs’ blood circulation time by minimizing its non-specific interactions with 
proteins in the bloodstream and immune system components, the surface charge of 
the DDL is important to take into account while formulating it. 
  
We altered the levels of several elements of the DDL formulation (cholesterol, 
DSCP and PEGylated lipids) and studied their role on the effective surface charge 
of the DDL resulting from its interactions with salts present in the bloodstream 
(NaCl, KCl and CaCl2).  
 
11.1.1 Role of cholesterol in the DDL and biological membrane 
 
Cholesterol is not only an important component of biological membranes (Van 
Meer et al. 2008; g et al. 2009), it is also a component of most FDA approved 
DDL formulations (Dawidczyk et al. 2014). Cholesterol plays a role in many of 
the membrane properties, including mechanical strength, elasticity, packing 
density and permeability. Here we report a novel role of cholesterol in the lipid 
membrane, it contributes to the surface charge of membrane bilayer. With our MD 
simulation studies we show that the presence of cholesterol results in a decrease in 
Na+ binding for the typical neutral (zwitterionic) phospholipid membranes (DSPC 
and POPC). The ζ-potential measurements carried out in parallel with our 
simulations showed decrease in its surface charge with increase in its cholesterol 
content. While cholesterol has been shown to alter several properties of the 
phospholipid membrane, this specific effect of altering the membrane charge is 
novel and has both biological and pharmaceutical relevance. 
 
It is known that surface charge strongly influences the interactions of 
biological membranes and DDLs with proteins (Townson et al. 2013; Pozzi et al. 
2014), however these interactions certainly involve more factors than surface 
charge alone. A significant amount of further study is required to understand this 
in full detail.  
 
 
11.1.2 DDLs composed of synthetic lipids 
 
Surface properties of DDLs govern their interactions with bloodstream proteins 
and also the release profile of encapsulated drug molecules. (Torchilin 1996) 
While so far the majority of DDLs have been composed of standard 
phospholipids, recently DDLs have also been formulated from novel synthetic 
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phospholipids with the aim of imparting specific desired properties to the DDL. 
(Zhao et al. 2012; Perttu et al. 2012). 
 
One such novel synthetic lipid is inverse phosphatidylcholine (CPe) (Perttu et 
al. 2012). The inverse phosphatidylcholine (CPe) lipids contain a phosphate group 
and choline group as PC lipids but the places of these groups are interchanged 
such that the phosphate group is at the membrane interface oriented out into the 
water and the choline group is directly attached to the lipid tails.  
 
When the physicochemical properties of the CPe formulated liposome was 
compared to the PC formulated ones, they were similar, except CPe formulated 
liposomes differed significantly in their surface charge and release profile of the 
encapsulated molecules. To understand the possible cause of these differences, we 
performed MD simulations of the membrane bilayers formulated with DLPC and 
DLCPe lipids with three salts found in the bloodstream, NaCl, KCl and CaCl2.  
 
The simulations studies revealed that CPe formulated membrane bilayers have 
a significantly larger area per lipid in comparison to the PC membrane bilayer. 
Also, there is a marked difference between the electrostatic potentials along the 
membrane normal of the CPe formulated bilayer as compared to the PC 
formulated bilayer. The difference in electrostatic potential of the PC and CPe 
formulated membrane bilayer is due to difference in the membrane-cation (Na+ 
and Ca2+) interactions. As indicated from the proportion of ions bound to the 
membrane and the mass density profile along the membrane normal, we could see 
that Na+ ions bind strongly to the PC headgroups of the membrane bilayer in 
comparison to the case for the CPe membrane bilayer. The K+ ions, however, do 
not show significant binding for both PC and CPe membrane headgroups. The 
Ca2+ ions binding to the lipid headgroups are observed for the cases of both the PC 
and CPe formulated liposomes.  
 
Together, size and surface charge of the DDL affect the release rate of 
encapsulated drug molecules. Hence, depending on biochemical characteristics of 
the drug, specific formulations of the DDL can be designed to control its release 
rate from the DDL. 
 
 
11.2 PEGylated DDLs  
 
DDLs are often PEGylated in order to reduce uptake by the RES (Harris & Chess 
2003) and increase uptake at tumor sites (Fang et al. 2011). The PEG polymer 
forms a protective polymer corona surrounding the DDL, which influences its 
surface properties. This in turn affects its interactions with proteins in the 
bloodstream. Hence obtaining a correct picture of the mechanisms involved in the 
PEG stealth sheath becomes crucial. We have examined the PEGylated DDL 
membrane bilayer with atomistic level resolution using MD simulation. To obtain 
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the surface structure of the PEGylated liposomes and factors affecting it we varied 
the concentration of different components of the DDL that are lipids, cholesterol 
and PEG and observed the interactions with salt ions in the bloodstream. 
 
11.2.1 Effect of PEG formulation density on surface structure of the DDL 
 
We systematically varied the PEG formulation density of the DDL from 5 to 10 
%, in both the absence and presence of NaCl at physiological concentration. 
Through MD simulations we demonstrated that at physiological salt concentration, 
the PEG layer expands due to Na+ binding to PEG oxygens. At 5 % PEG 
formulations density, Na+ ions bind to the membrane bilayer in addition to the 
PEG oxygen, and Cl- ions collocate to the PEG layer, but do not show any 
binding. This binding of Na+ to PEG oxygen and co-localization of Cl- ions in the 
PEG layer results in a neutral charge layer in the PEG layer. However, when the 
PEG formulation density is increased to 10 %, Na+ ions do show binding to the 
PEG oxygens but Cl- ions do not co-localize with the PEG layer as the membrane 
structure is tighter and the Cl- ions are expelled from the PEG layer. Due to this 
exclusion of Cl- ions from the PEG layer, a negatively charged layer is formed 
above the PEG layer and the PEG layer is now positively charged due to 
association with the Na+ ions.  This results in an effective charged double layer on 
the DDL surface. 
 
We also compared the extent to which Na+, K+, and Ca2+ ions bind to the 
membrane headgroups and PEG oxygens. We observed that Na+ interacts strongly 
with PEG oxygen in comparison to the K+ ions, whereas the Ca2+ ions do not 
interact with the PEG oxygen at all. They however interact very strongly with the 
membrane headgroups and the Cl- ions. 
 
These results provide a possible explanation for the results of the in vitro studies 
reported by Bronich et al. and Holland et al. The Ca2+ ions crosslink the 
headgroups of two separate liposomes, and thus induce liposome fusion. In both 
experimental studies it was observed that crosslinking between the liposomes is 
inhibited in the presence of Ca2+ ions when they are PEGylated. In the presence of 
PEG, Ca2+ ions do not bind to PEG oxygen at all and are located outside of the 
PEG layer, acting as a steric barrier to fusion. 
 
11.2.2 Role of cholesterol in PEGylated DDL  
 
To study the role of cholesterol in the PEGylated DDL, we incorporated 
cholesterol into the PEGylated membrane bilayer and varied its concentration 
systematically from 0 to 50 % molar fraction. 
 
We observed that the PEG polymer enters the DSPC membrane bilayer only when 
cholesterol is included in the formulation. This results in an increase in the area 
per lipid of the DDL with increase in cholesterol. Also, the PEG polymer enters 
the lipid bilayer in the presence of cholesterol in a very specific way, such that it 
interacts only with the β-side of the cholesterol. This shows that the PEG polymer 
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plays a role in the overall membrane bilayer structure and will affect its properties 
including membrane permeability and stability. 
 
Results obtained from MD simulations provided a possible explanation for the 
previously reported in vitro studies. Nikolova et al studied the effect on 
permeability of encapsulated D-glucose from the liposome by varying its PEG 
formulation density (Nikolova & Jones 1996). They reported that with an initial 
increase in the PEG formulation density up to 5 %, the permeability decreases, 
however in the range of 5-7 % PEG formulation density, there is an increase in the 
permeability for D-glucose. In another study, Garbuzenko et al. studied the effect 
of PEG formulation density on liposome size (Garbuzenko et al. 2005). They 
observed that liposome size is inversely proportional to the PEG formulation 
density up to a level of ~7 %. There is, however an anomalous increase in 
liposome size with further increase in the PEGylated lipid content.  
 
Both of the above mentioned observations were previously attributed to the 
transition in the structure of the PEG corona from the mushroom regime to the 
polymer brush regime, resulting from the increasing density of bound polymer on 
the surface. As evident from our MD simulation studies of PEGylated bilayers, we 
consistently observed PEG to enter in membrane bilayers in the presence of 
cholesterol. Also as PEG enters the membrane bilayer it interferes with membrane 
structuring and, hence, will influence the release rate of the encapsulated 
molecules in the DDL. 
 
In addition, Janout et al. observed that for the case of the PEGylated liposomes 
with cholesterol, PEG is capable of stimulating the release of cholesterol from the 
liposomes (Janout et al. 2012). In our simulations we did not observe this 
mechanism directly, however our results suggest this might be possible, as PEG 
enters the DDL membrane bilayer and interacts specifically only with cholesterol 
in all the cases. As indicated by mass density profile, we observed that due to this 
interaction, cholesterol shifts toward the membrane water interface in comparison 
to non-PEGylated liposome bilayers.  
 
We studied the effect of cholesterol on the surface structure of the PEGylated 
DDL and provided the first model at atomistic resolution for the Doxil® 
formulation that is the first FDA approved PEGylated DDL. This model can be 
used in future MD studies to investigate interactions with proteins. 
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11.3 Targeted DDL 
 
In order to reduce off target effects and increase the concentration of the 
PEGylated DDL at the specific target site, the PEGylated DDL can be conjugated 
with a targeting moiety. The targeting moiety achieves this by binding to specific 
receptors present on the surface of target cells.  
 
The novel neovasculature endothelium targeting moiety, AETP, was identified 
through phage display experiments. The AETP moiety is a polypeptide, 
predominantly consisting of hydrophobic amino acids. The AETP moiety was 
conjugated with the PEGylated DDL to achieve an increase in target cell affinity 
and greater accumulation at the tumor site as compared to non-targeted PEGylated 
DDL.  However, as observed in both in vitro and in vivo experiments, this was not 
the case. Thus, the AETP moiety was not able to provide the desired targeting 
efficacy. As the AETP moiety is hydrophobic in its biochemical nature, it was 
thought to be interacting with the hydrophobic lipid tails of the DDL membrane 
bilayer. As this was difficult to validate with the experiments alone, we performed 
molecular dynamics simulations of the conjugated AETP moiety with the 
PEGylated DDL and molecular docking studies of the AETP moiety with HSA to 
understand possible promiscuous interactions. Molecular dynamics simulations 
revealed that AETP does not enter into the membrane core but it is instead 
covered by PEG polymer. This excessive coverage of the AETP moiety with PEG 
polymer could potentially mask its interaction with the intended target site. 
Furthermore molecular docking studies suggest that the AETP moiety has a higher 
binding affinity towards HSA (predominantly present in blood plasma). This 
binding of AETP to the HSA could be an additional factor in not achieving 
targeted drug delivery.  
 
Thus molecular modelling studies showed that PEG might not be a suitable 
choice for AETP targeted DDLs and alternative protective polymer could be used 
to address the issue. The search for possible alternatives to PEG is an active field 
of research and Knop et al. have already reported some of the possible alternatives 
for the PEG polymer. The combined approach of molecular modelling methods 
coupled with in vitro and in vivo studies is capable of characterizing the potential 
interactions of these alternative protective polymers and components of the DDL 
and can help construct effective DDLs in the future. 
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12. Conclusions 
1. With increasing cholesterol concentration from 0 to 50 % in lipid bilayer 
(DSPC and POPC) in presence of saline, in silico we find that the number 
of Na+ ions binding to the membrane headgroups decreases. The in vitro 
validation by zeta potential measurements confirmed these results by 
showing the same trend; the zeta potential of the DSPC and POPC 
liposomes decreased with increase in cholesterol content. 
  
2. By reversal of the phosphatidylcholine group to CPe (where the phosphate 
group faces the membrane interface instead of the choline), with all-atom 
MD simulations we report that binding of Na+, K+ and Ca2+ ions is reduced. 
This affects the membrane zeta potential and thus surface charge of the 
membrane bilayer. These results provide an explanation to the experiment 
that showed a drop in zeta potential of the CPe liposomes when compared 
with PC liposome in presence of Ca2+ ions. 
 
3. Increasing the formulation density of PEGylated lipid from 5 to 10 % 
decreased the extent to which the Cl− ions penetrated the PEG layer. This 
makes the PEG layer effectively positively charged. The interaction of the 
PEG with the K+ ions was weaker than for the Na+ ions, and non-existent 
for the Ca2+ ions. Our results provide an explanation for the experimental 
observation of the mechanisms through which PEG may inhibit uptake of 
the liposome by the RES and also a possibility that calcium induced 
membrane fusion is inhibited.  
 
4. In presence of cholesterol, PEG enters into the lipid bilayer in a very 
specific orientation; the PEG winds along the β face of the cholesterol. 
Also, when the membrane is PEGylated, the area per lipid increases rather 
than decreases, due to interactions with cholesterol. This study provides 
mechanistic explanations for the existing experimental results concerning 
the effect of adding cholesterol to the PEGylated liposome. 
 
MD simulations show that novel AETP targeting moieties were located deep in 
the PEG layer of the liposomes, and thus affect the interactions with target 
receptors. Also, molecular docking shows that peptide binding to HSA may 
further inhibit target binding 
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13. Future prospects 
Drug delivery liposomes: Integration of in vitro and in vivo with in silico 
methods 
 
Liposome based drug delivery approaches have already demonstrated great 
promise to tackle diseases such as cancer (Fonseca et al. 2014). Recent studies are 
moving toward targeted DDLs and nanoparticles in general. The research is 
increasing in this area, reflected in the number of publications in the field 
(>20000), however only few of these potential drugs make it into clinical trials. 
 
The development of novel DDLs faces many technical challenges, which are 
described previously. These include structural stability of the DDL, short half-life 
in the bloodstream and limited accumulation at the target site. As the composition 
of DDLs and their surface structure are responsible for the nature of its 
interactions with proteins in the blood plasma, there is a need to understand the 
physicochemical properties of the DDLs (Townson et al. 2013). 
 
It has recently been established that once liposomes enter into the bloodstream, 
they loose their synthetic identity (Pozzi et al. 2014). With specific and non-
specific interactions of the DDL surface with elements of the bloodstream such as 
ions, serum proteins etc. This new bio–nano interface around the DDL is termed 
as a protein corona(Caracciolo et al. 2010). This protein corona decides the fate of 
the DDL in the bloodstream. (Cedervall, Lynch, Lindman, et al. 2007b; Nel et al. 
2009; Lundqvist et al. 2008; Lindman et al. 2007; Cedervall, Lynch, Foy, et al. 
2007a).   
 
Recent studies with respect to charecteriztion of the protein corona include 
understanding of nanoparticle surface properties and size (Lundqvist et al. 2008), 
binding with HSA (Lindman et al. 2007), identification of specific plasma proteins 
(Nel et al. 2009) and characterization of these interactions as specific or non-
specific ones (Cedervall, Lynch, Lindman, et al. 2007). Most recent work along 
these lines includes the effect of PEG chain length on bio-nano interface formation 
in cancer cells (Wolfram et al. 2014). 
 
While these efforts are attempting to provide detailed kinetics and interactions 
of the DDLs with proteins in the bloodstream there have been some puzzling 
findings. One of the recent in vitro study reports that, upon incubation of serum 
with liposomes (PEGylated and non-PEGylated), the liposomes decreased in size 
(Wolfram et al. 2014). Also Townson et al. (Townson et al. 2013) showed for the 
first time that, despite having identical components, size and surface charge; the 
nanoparticle differing in only the spatial arrangement of surface groups, showed 
completely different in vivo results. Molecular dynamics simulations can attempt 
to answer these questions as all the interactions can be observed and the properties 
can be understood at atomic level of resolution.  
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As the current experimental efforts are on-going, they can be coupled with MD 
simulation studies with model membrane bilayers of PEGylated and non-
PEGylated liposomes with proteins. These simulations can certainly help look at 
interactions of DDLs in greater details. For more comprehensive studies, however, 
more coarse grained simulations such as martini models of the membrane bilayer 
with proteins of interest can be used (Periole & Marrink 2013). 
 
I hope that findings presented in our studies can help build an understanding of 
specific and non-specific interactions of DDLs with proteins of the blood plasma 
and immune system. Once these interactions are understood in greater details, the 
novel DDLs can be designed for specific drug delivery purposes and help move 
the research in targeted drug delivery forward, in a hypothesis driven way.  
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